Hot in Healthcare 2019
is in the works!



Register now


Hot in Healthcare 2019 will be taking place on Thursday 19 September. Join key players from the medtech, biotech and pharma sector at this all-day Benelux life sciences event in Amsterdam to share knowledge, (re)connect and find out what’s hot in healthcare!

The life sciences and healthcare industry is in flux. With technology and innovation reshaping the boundaries of health and healthcare, how do you remain ahead of the curve? How can you add value and contribute to a healthier system?

Hot in Healthcare 2019 is organized by Baker McKenzie in collaboration with Kempen, HollandBIO and

The first part of our event, Life Sciences Dealmakers, will be organized in collaboration with Kempen. The morning session kicks off with keynote speaker Rudi Pauwels (founder of Tibotec-Virco and Biocartis), and offers the opportunity to schedule 1-on-1s with investors. During workshops with scale-ups, investors, VC firms and industry players (medtech, biotech and pharma), the morning will address the latest topics in today’s and tomorrow’s deal making. Panelists include Geraldine O’Keeffe (Partner at LSP), and be sure not to miss the session with Edwin Moses (former CEO of Oxford Asymmetry and Ablynx) in the Hot Seat.

The afternoon session, Future of Healthcare, will focus on the sustainability of healthcare companies, covering topics such as the impact of artificial intelligence, circularity in healthcare and how to face regulatory challenges. Lucien Engelen will deliver the keynote speech, and panelists include Robert Metzke (Philips’ Global Head of Sustainability) and Mark-Jan Harte (CEO at Aidence). In the legacy of last year’s ‘coalition of the doing,’ we look forward to gathering stakeholders from across the spectrum to inspire and find common ground on how to make healthcare future proof.

Follow our LinkedIn page for all updates, program announcements and the reveal of more exciting speakers in the next few weeks.

Secure your spot at Hot in Healthcare 2019 now and pre-register!
* Please note that pre-registration does not guarantee access to the event, as places are limited. 

Confirmed speakers

Stay tuned as we add more speakers to the line-up!

Lucien Engelen

Keynote speaker

CEO / Fellow Transform.Health / Center for the Edge Deloitte

We are in the midst of a digital transformation across society that brings opportunities and challenges. What used to work isn’t good enough anymore in a world that is increasingly becoming digital.

Through his small company Transform.Health as a vehicle, Lucien operates at the convergence of Innovation & Strategy for executive boards, governments, corporates, and professionals via his role as Edge Fellow for the Deloitte Center for the Edge (Amsterdam, Melbourne and San Francisco), at Exponential Medicine (since 2011) at Singularity University in Silicon Valley, the Netherlands as well as currently in the Nordics.

Rudi Pauwels

Keynote speaker

Founder & President Praesens Foundation (former Tibotec-Virco and Biocartis)

Dr. Rudi Pauwels is a scientist and serial bio-tech entrepreneur (pharmaceuticals & diagnostics).

He started at the Rega Institute (Belgium) where he described in the mid-eighties the first methods to search for anti-HIV drugs. His work led to several new anti-HIV compounds including the discovery in 1988 of the nucleotide class of HIV RT inhibitors (e.g. adefovir, tenofovir) and in 1990 the first description of the NNRTI-class of compounds. He (co)-founded several companies in the field of anti-HIV treatment (Tibotec) and diagnostics (Virco, drug resistance testing). The R&D efforts at Tibotec would lead to three next generation anti-HIV drugs: the protease inhibitor darunavir (PREZISTA™), the NNRTI’s etravirine (INTELENCE™) and rilpivirine (EDURANT™). In 1999, he was the driving force behind the creation of Tibotec-Crucell joint-spin off Galapagos Genomics. He headed for a few years the anti-infective (HIV, HCV, TB) drug discovery efforts of Johnson & Johnson. In 2004 Dr. Pauwels went on a 3-year sabbatical at the Swiss Federal Institute of Technology EPFL to deepen his knowledge in micro- and nanotechnology. Driven by the increasing need for more rapid and easy-to-use diagnostics to enable personalized medicine in closer proximity of the patients, he founded Biocartis in 2007.

After leading the company for nearly a decade, he decided in 2017 to focus again on infectious diseases and technology innovation. Inspired by his experiences in West Africa during the Ebola outbreak, he created the Praesens Foundation that is developing, providing and implementing easy to train and use solutions that contribute to better epidemic preparedness, early warning and rapid response for existing and emerging infectious diseases and medicine in general.

Robert Metzke


Chief of Staff Innovation & Strategy and Head of Sustainability Philips

Robert is an experienced global program and team leader with passion for innovation, strategy, social impact and change leadership.

He currently holds a double role as Head of Sustainability and Chief of Staff Innovation & Strategy at Royal Philips.

As Head of Sustainability, Robert has been driving the company strategy towards innovative, sustainable business models. In particular, Robert and his team are leading the Healthy People, Sustainable Planet program (, which embeds sustainability thinking across all sectors of the company.

In his role as Chief of Staff, he is responsible for initiating and driving strategic initiatives across Innovation, Strategy, Design, IP&S, and Sustainability.

Before joining Philips, Robert worked at McKinsey & Company as consultant where he gained 5 years of experience in strategy and innovation in the high-tech, health-care and public sectors.

Edwin Moses

'Hot seat' interview

Chairman Achilles Therapeutics, Evox Therapeutics and Virion Biotherapeutics

Dr. Edwin Moses is a serial entrepreneur in life science companies. As CEO, he built two businesses (Oxford Asymmetry International plc and Ablynx nv), led their successful IPOs on the LSE, EuroNext and NASDAQ and raised over €500M in equity and debt financing.

He ran the sales process for each company generating values of £316M and €3.9Bn respectively. At Ablynx, Edwin ensured that the novel Nanobody technology platform was used to build a broad product pipeline, including Cablivi™ which was recently approved for use in both Europe and the USA. In addition, he helped secure pharmaceutical collaborations with a potential value of >€10Bn. Edwin has expertise in high value service provision to the pharmaceutical industry and in drug discovery and development, with more than 25 years of Board level experience in >15 companies. He is currently Chairman of Achilles Therapeutics, Evox Therapeutics and Virion Biotherapeutics.

Geraldine O'Keeffe


Partner LSP

Geraldine O’Keeffe joined LSP in 2008. She became a Partner of the firm in 2010. Geraldine’s prime focus and responsibility within LSP is to invest in listed securities.

Prior to joining LSP, she held the position of Senior Healthcare Analyst at Fortis Investment Banking. In that position, she researched a wide range of innovative life sciences companies, both in Europe and the US. Geraldine brings strong analytical and investment skills to the LSP team. Before joining the financial community, she worked within the life sciences industry for a number of years, gaining first-hand product development experience in a commercial setting. Prior to working in the industry, she lectured in Biomedical Sciences for several years at the Dublin Institute of Technology. Geraldine has a very strong scientific background, including a Bachelor’s degree in Biochemistry and Microbiology from University College Cork and a Master’s degree in Biotechnology from University College Galway. She also conducted post-graduate research, inter alia at the prestigious Max Planck Institute for Biophysical Chemistry in Göttingen, Germany. In addition, Geraldine is also a graduate of The Dublin School of Business.

Mark-Jan Harte


CEO and Co-Founder Aidence

Mark-Jan is CEO and co-founder of Aidence. He began his path to founding Aidence more than 20 years ago after completing a masters in Computer Science at the Technical University Eindhoven. This path then led him to occupy various roles in software including IT architecture in finance, founding and exiting a consumer software company and machine learning consultancy.

Why Mark-Jan is excited about applying AI to the healthcare industry: “AI is fascinating because you can build something that is better at a given task than you are yourself. That allows humanity to bootstrap itself and achieve things that were unimaginable until very recently. In healthcare especially there is a huge opportunity to apply this power for the benefit of all.”

Jan De Kerpel

Moderator (morning session)

Managing Director, Life Sciences & Healthcare Kempen

Jan De Kerpel is a seasoned biotech/healthcare business and finance expert with more than 20 years of combined experience in the fields of drug development, equity and growth financing.

Jan brings a unique blend of business, scientific and financial knowledge to enhance the development of high-growth life science companies. He has a proven track record in successfully identifying investment opportunities to a continuously expanding international investor basis and have been instrumental in raising €Bns in equity financing for numerous European biotech, medtech, diagnostics, health services and pharmaceutical companies.

Prior to Kempen, he was a senior equity analist at KBC Securities responsible for the biotech/healthcare sector in the Benelux. Before turning to the investment banking world, he was an R&D director at Devgen (now Syngenta) and senior scientist at Tibotec-Virco (now JNJ), involved in drug development and project-, team-, and business development. His team-work resulted in several commercial products, not only creating shareholder value, but having a life-saving impact for many people around the world.

Academically: master and PhD in life sciences (KULeuven, Belgium), postgraduate in Business Administration (KULeuven) and an executive MBA (Vlerick Business School), corporate finance classes (KUBrussel).

Toggle Menu